New developments in the therapy of chronic hepatitis B. What are the indications for nucleoside analogues?;Neue entwickdungen in der therapie der chronischen hepatitis B. Warm sind nukleosidanaloga indiziert?

Zeitschrift fur Gastroenterologie

Volumn 38, Issue 1, 2000, Pages 77-87

  Petry, Wolfgang ^a   Erhardt, A ^b   Heintges, T ^b   Haussinger D ^b  

^a HEINRICH HEINE UNIVERSITY   (Germany)

^b NONE

Author keywords

Chronic hepatitis B therapy; Interferon; Lamivudine famciclovir; Nucleoside analogues; Treatment

Indexed keywords

ADEFOVIR; ALPHA INTERFERON; FAMCICLOVIR; LAMIVUDINE; NUCLEOSIDE ANALOG; ADENINE; ANTIVIRUS AGENT; DRUG DERIVATIVE; PHOSPHONIC ACID DERIVATIVE; RNA DIRECTED DNA POLYMERASE INHIBITOR;

CHRONIC HEPATITIS; DNA HYBRIDIZATION; DRUG TOLERABILITY; HEPATITIS B; HUMAN; LIVER TRANSPLANTATION; LONG TERM CARE; REVIEW; TREATMENT CONTRAINDICATION; TREATMENT INDICATION; VIRUS RESISTANCE; RECURRENT DISEASE;

ADENINE; ANTIVIRAL AGENTS; HEPATITIS B, CHRONIC; HUMANS; INTERFERON-ALPHA; LAMIVUDINE; LIVER TRANSPLANTATION; LONG-TERM CARE; PHOSPHONIC ACIDS; RECURRENCE; REVERSE TRANSCRIPTASE INHIBITORS;

EID: 0033622201     PISSN: 00442771     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2000-14851     Document Type: Review

References (81)

1. Liaw Y, Tai D, Chu C, Chen T. The development of cirrhosis in patients with chronic type B hepatitis. A prospective study. Hepatology 1988; 8: 493-6
2. Fattovich G, Giustina G, Schalm SW et al. Occurrence of hepatocellular carcinoma and decompensation in Western European patients with cirrhosis type B. Hepatology 1995; 21: 77-82
3. Ikeda K, Saitoh S, Koida I et al. A multivariate analysis of risk factors for hepatocellular carcinogenesis: A prospective observation of 795 patients with viral and alcoholic cirrhosis. Hepatology 1993; 18: 47-53
4. Kato Y, Nakata K, Omagari K et al. Risk of hepatocellular carcinoma in patients with cirrhosis in Japan. Cancer 1994; 74: 2234-8
5. Retry W, Heintges T, Hensel F et al. Hepatozelluläres Karzinom in Deutschland. Epidemiologie, Ätiologie, Klinik und Prognose bei 100 konsekutiven Patienten einer Universitätsklinik. Z Gastroenterol 1997; 35: 987-97
6. Petry W, Erhardt A, Niederau C, Häussinger D. Hepatozelluläres Karzinom bei HCV-Infektion. In: D. Häussinger, C. Niederau (eds.): Hepatitis C. Blackwell Wissenschaft. Berlin, 1997, 183-219
7. Wong DK, Cheung AM, O'Rourke K et al. Effect of alpha-interferon treatment in patients with hepatitis B e antigen-positive chronic hepatitis B. A meta-analysis. Ann Intern Med 1993; 119: 312-23
8. Niederau C, Heintges T, Lange S et al. Long-term follow-up of HBeAg-positive patients treated with Interferon alfa for chronic hepatitis B. N Engl J Med 1996; 334: 1422-7
9. Gilson RJC. Murray-Lyon IM, Nelson MR et al. Extended treatment with adefovir dipivoxil in patients with chronic hepatitis B virus infection. Hepatology 1998; 28 (4 Pt2): 491A
10. Hopf U, Niederau C, Kleber C, Fleig WE. Behandlung der chronischen Virushepatitis B/D und der akuten und chronischen Virushepatitis C. Konsensus der Deutschen Gesellschaft für Verdauungs-und Stoffwechselkrankheiten. Z Gastroenterol 1997; 35: 971-86
11. Cohard M, Poynard T, Mathurin POS, Zarski JP. Prednisone-interferon combination in the treatment of chronic hepatitis B: Direct and indirect metaanalysis. Hepatology 1994; 20: 1390-8
12. Lai CL, Chien RN, Leung NWT et al. A one year trial of lamivudine for chronic hepatitis B. N Engl J Med 1998; 339: 61-8
13. Dienstag JL, Schiff ER, Wright TL et al. Lamivudine as initial treatment for chronic hepatitis B in the United States. N Engl J Med 1999; 341: 1256-63
14. Liaw Y-F. Chien R-N. Yeh C-T, Tsai S-L. Chu C-M. Acute exacerbation and hepatitis B virus clearance after emergence of YMDD motif mutation during Lamivudine therapy. Hepatology 1999; 30: 567-72
15. Heathcote J, Schalm SW, Cianciara J et al. Lamivudine and Intron A combination treatment in patients with chronic hepatitis B infection. J Hepatol 1998; 28 (suppl. 1): 43
16. Dienstag JL, Perrillo RP, Schiff ER et al. A preliminary trial of lamivudine for chronic hepatitis B infection. N Engl J Med 1995; 333: 1657-61
17. Lai CL, Yuen MF, Chcng CC et al. An open comparative study of lamivudine and famciclovir in the treatment of chronic hepatitis B infection. Hepatology 1998; 28 (4 Pt2): 318A
18. De Man RA, Habal F, Marcellin P et al. A randomized placebo-controlled study on the efficacy of 12-months famciclovir treatment in with chronic HBeAg+hepatitis. J Hepatol 1999; 30 (suppl. 1): 59
19. Chow, WC, Ng KY, Mesenas S, Law NM, Ng HS. The interim results of thymosin alpha 1 in a randomized controlled study in the treatment of chronic hepatitis B patients: Singapore experience. Hepatology 1998; 28 (4 Pt2): 586A
20. Gao T, Jiang WL, Wang WK, Gu SM, Wu SM. Safety and efficacy of thymosin alpha 1 monotherapy in Chinese patients with chronic hepatitis B. Hepatology 1998; 28 (4 Pt2): 725A
21. Chien R-N, Liaw Y-F, Chen T-C, Yeh C-T, Sheen I-S. Efficacy of thymosin-alpha 1 in patients with chronic hepatitis B: A randomized, controlled trial. Hepatology 1998; 27: 1383-7
22. Andreone P, Cursaro C, Gramenzi A et al. A randomized controlled trial of thymosin-alpha 1 versus Interferon alpha treatment in patients with HBeAk and hepatitis B virus DNA-positive chronic hepatitis B. Hepatology 1996; 24: 774-7
23. Zavaglia C, Severini R, Tinelli C et al. A randomized controlled trial of thymosin alpha 1 therapy for anti-HBe/HBV-DNA-positive chronic hepatitis B. Hepatology 1998; 28 (4 Pt2): 725A
24. Lu ZM, Gao J, Yao GB et al. A comparative trial of thymosin alone and thymosin plus alpha interferon in the treatment of Chinese patients with chronic hepatitis B. Hepatology 1997; 26 (4 Pt2): 426A
25. Lau GKK, Kwok A, Karlberg J et al. A twenty six weeks trial of thymosin alpha 1 plus famciclovir in the treatment of Chinese immune tolerant adult patients with chronic hepatitis B. Hepatology 1998; 28 (4 Pt2): 216A
26. Teuber G, Dienes HP, Meyer zum Büschenfelde KH, Gerken G. Interferon-alpha-Retherapie der chronischen Hepatitis-B-und -C-Virusinfektion. Z Gastroenterol 1995; 33: 94-8
27. Janssen HL, Schalm SW, Berk L, de Man RA, Heijtink RA. Repeated courses of alpha-interferon for treatment of chronic hepatitis type B. J Hepatol 1993: 17 (suppl. 3): S47-51
28. Schiff E, Karayalcin S, Grimm I et al. A placebo controlled study of lamivudine and Interferon alpha-2b in patients with chronic hepatitis B who previously failed Interferon therapy. Hepatology 1998: 28 (4 Pt2): 388A
29. Mutimer D, Naoumov N, Honkoop P et al. Combination alpha-interferon and lamivudine therapy for alpha-interferon-resistant hepatitis B infection: Results of a pilot study. J Hepatol 1998; 28: 923-9
30. Heintges T, Petry W, Kaldewey M, Erhardt A, Niederau C, Häussinger D. Die Kombination von Alpha-Interferon und HBs-Ag-Vakzinierung führt zu hohen Ansprechraten bei Interferon Non-Respondern mit chronischer Hepatitis B. Z Gastroenterol 1999; 37: 96 (Abstract)
31. Pol S, Driss F, Michel ML et al. Specific vaccine therapy in chronic hepatitis B infection. Lancet 1994; 344: 342
32. Samuel D, Muller R, Alexander G et al. Liver transplantation in European patients with the hepatitis B surface antigen. N Engl J Med 1998; 329: 1842-7
33. Samuel D, Bismuth A, Mathieu D et al. Passive immunoprophylaxis after liver transplantation in HBsAg-positive patients. Lancet 1991; 337: 813-5
34. Grellier L, Mutimer D, Ahmed M et al. Lamivudine prophylaxis against reinfection in liver transplantation for hepatitis B cirrhosis. Lancet 1996, 348: 1212-15
35. Ben-Ari Z, Zemel R, Kazatsker A, Fraser G, Tur-Kaspa R. Efficacy of lamivudine in patients with hepatitis B virus pre-core mutant infection pre-and post-liver transplantation. J Hepatol 1998; 28 (suppl. 1): 153
36. Singh NEG, Gayowski T, Wannstedt CF, Wagener MM, Marino IR. Pretransplant famciclovir as prophylaxis for hepatitis B virus recurrence after liver transplantation. Transplantation 1997; 63: 1415-9
37. Bonner KC, Rosen HR, Flora KD. Famciclovir treatment of decompensated HBV-cirrhosis. Hepatology 1996; 24 (4 Pt2): 282A
38. Manns M, Neuhaus P, Schoenhorn H, Griffin K. Famciclovir treatment of hepatitis B infection in patients with end-stage liver disease. J Hepatol 1998; 28 (suppl. 1): 114
39. Villeneuve JP, Bilodeau M, Fenyves D et al. Suppression of hepatitis B virus replication by lamivudine results in improvement of liver function in patients with severe cirrhosis. Hepatology 1997; 26 (4 Pt2): 430A
40. Sponseller CA, Smith-Wilkaitis NEG, Bacon BH, Di Bisceglie AM. Clinical improvement in patients with decompensated liver disease due to hepatitis B following treatment with lamivudine. Hepatology 1998; 28 (4 Pt2): 589A
41. Andreone P, Caraceni P, Grazi GL et al. Lamivudine treatment for acute hepatitis B after liver transplantation. J Hepatol 1998; 29: 985-9
42. Dodson SF, Balan V, Shakil O et al. Lack of efficacy of lamivudine for HBV-infection alter liver transplantation. Hepatology 1998: 28 (4 Pt2): 262A
43. Perrillo R, Rakela J, Martin P et al. Long-term lamivudine therapy of patients with recurrent hepatitis B post liver transplantation. Hepatology 1997; 26 (4 Pt2): 177A
44. Prieto M, Cordoba J, Ravon JM et al. Good response to lamivudine therapy in patients with de novo hepatitis B following orthotopic liver transplantation: A pilot study. Hepatology 1998; 28 (4 Pt2): 348A
45. McCaughan G, Koorey D, Verran D et al. Prophylactic lamivudine (L.) and very low dose HBIG prevent HBV recurrence post liver transplant whilst rescue therapy with L. is associated with significant resistance and graft loss. Hepatology 98: 28 (4 Pt2): 263A
46. Perrillo R, Rakela J, Dienstag J et al. Multicenter study of Lamivudine therapy for hepatitis B after liver transplantation. Hepatology 1999; 29: 1581-6
47. Rabinowitz M, Dodson F, Rakela J. Famciclovir for recurrent hepatitis B infection after liver transplantation. Hepatology 1996; 24 (4 Pt2): 282A
48. Krüger M, Tillmann HL, Trautwein C et al. Famciclovir treatment of hepatitis B virus recurrence after liver transplantation: A pilot study. Liver Transplant Surg 1996; 2: 253-62
49. Jaeckel K, Tillmann HL, Krueger M et al. Resistance against nucleoside analogues in patients after liver transplantation for hepatitis B cirrhosis. Hepatology 1998; 28 (4 Pt2): 235A
50. Roche B, Samuel D, Feray C et al. Long-term ganciclovir therapy for hepatitis B virus infection after liver transplantation. Hepatology 1996: 24 (4 Pt2): 568A
51. Gish RG, Lau JY, Brooks L et al. Ganciclovir treatment of hepatitis B virus infection in liver transplant recipients. Hepatology 1996; 23: 1-7
52. Perrillo RP, Schiff ER, Dienstag JL et al. Lamivudine for prevention of recurrent hepatitis B after liver transplantation: Final results of a U.S/Canadian multicenter trial. Hepatology 1999; 30 (4 Pt2): 222A
53. Terrault NA Wright TL, Roberts JP et al. Combined short-term hepatitis B immunglobulin (HBIG) and long-term lamivudine (LAM) versus HBIG monotherapy as hepatitis B virus prophylaxis in liver transplant recipients. Hepatology 1998; 28 (4 Pt2): 389A
54. Han SH, Martin P, Markowitz J et al. Long-term combination HBIG and lamivudine is highly effective in preventing recurrent hepatitis B in orthotopic liver transplant recipients. Hepatology 1998; 28 (4 Pt2): 222A
55. Markowitz JS, Martin P, Conrad AJ et al. Prophylaxis against hepatitis B recurrence following liver transplantation using combination lamivudine and hepatitis B immune globulin. Hepatology 1997; 26 (4 Pt2): 152A
56. Bartholomew MM, Jansen RW, Jeffers LJ et al. Hepatitis-B-virus resistance to lamivudine given for recurrent infection after orthotopic liver transplantation. Lancet 1997; 349: 20-2
57. Allan MI, Deslauriers M, Andrews CW et al. Identification and characterization of mutants in hepatitis B virus resistant to lamivudine. Hepatology 1998; 27: 1670-7
58. Gutfreund KS, Fischer KP, Bain VG et al. Genotypic succession of mutations of the HBV polymerase associated with lamivudine resistance in chronic hepatitis B and liver transplantation. Hepatology 1998; 28 (4 Pt2): 487A
59. Buti M, Cotrina M, Jardi R et al. Different incidence of genomic resistance to lamivudine in chronic hepatitis B between HBeAg and anti-HBe positive patients. Hepatology 1998; 28 (4 Pt2): 589A
60. Da Silva LC, Pinho JRR, Sitnik R et al. Virologic factors associated with non response to lamivudine and viral mutations associated with drug resistance in Brazilian patients with chronic hepatitis B. Hepatology 1998: 28 (4 Pt2): 726A
61. Lau DTY, Ghany MG, Doo E et al. Features of response and resistance to lamivudine in patients with chronic hepatitis B with and without HBeAg. Hepatology 1998; 28 (4 Pt2): 318A
62. Lau DTY, Doo E, Ghany MG et al. Lamivudine for chronic hepatitis B with typical and atypical serology. Hepatology 1997; 26 (4 Pt2): 429A
63. Honkoop P, de Man RA, Niesters HGM, Schalm SW. Clinical impact of lamivudine resistance in chronic hepatitis B. J Hepatol 1998; 29: 510-11
64. Chayama K, Suzuki Y, Kobayashi M et al. Emergence and take over of YMDD motif mutant hepatitis B virus during long-term lamivudine therapy and re-take over by wild type after cessation of therapy. Hepatology 1998; 27: 1711-6
65. Marzano A, Debernardi-Venon W, Condreay L et al. Efficacy of lamivudine re-treatment in a patient with hepatitis B virus (HBV) recurrence after liver transplantation and HBV-DNA break-through during the first treatment. Transplantation 1998; 65: 1499-2000
66. Wolters LMM, Honkoop P, Niesters HGM, de Man RA. Efficacy of famciclovir treatment in chronic hepatitis B patients with different mutations at position 552 of the polymerase gene. J Hepatol 1998; 28: 909-10
67. Aye TT, Bartholomeusz Al, Shaw T et al. Hepatitis B virus polymerase mutations during antiviral therapy in a patient following liver transplantation. J Hepatol 1997; 26: 1148-53
68. Xiong X, Yang H, Westland CE, Toole JJ, Gibbs CS. Human hepatitis B virus DNA polymerases which contain mutations arising during famciclovir treatment remain sensitive to adefovir. Hepatology 1998; 28 (4 Pt2): 491A
69. Xiong X, Flores C, Yang H, Toole JJ, Gibbs CS. Mutations in hepatitis B DNA polymerase associated with resistance to lamivudine do not confer resistance to adefovir in vitro. Hepatology 1998; 28:1669-73
70. Hutchinson JG, Gordon SC, Schiff ER et al. Interferon alpha-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. N Eng] J Med 1998; 339: 1485-92
71. Poynard T, Marcellin P et al. Randomised trial of interferon alpha 2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha 2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. Lancet 1998; 352: 1426-32
72. EASL International Consensus Conference on Hepatitis C. Consensus Statement. J Hepatol 1999; 30: 956-61
73. Fried MW, Fong T-L, Swain MG et al. Therapy of chronic hepatitis B with a 6-months course of ribavirin. J Hepatol 1994; 21: 145-50
74. Brook MG, Karayiannis POS, Thomas HC. Which patients with chronic hepatitis B virus infection will respond to a alpha-interferon therapy? A statistical analysis of predictive factors. Hepatology 1989; 10: 761-3
75. Brook MG, McDonald JA, Karayiannis P et al. Randomised controlled trial of interferon alpha 2A (rbe) (Roferon-A) for the treatment of chronic hepatitis B virus (HBV) infection: Factors that influence response. Gut 1989; 30: 1116-22
76. Zylberberg H, Jiang J, Pialoux, G et al. Alpha-interferon for chronic active hepatitis B in human immunodefiency virus-infected patients. Gastroenterol Clin Biol 1996; 20: 968-71
77. Wong DK, Yim C, Naylor CD et al. Interferon alfa treatment of chronic hepatitis B: Randomized trial in a predominantly homosexual male population. Gastroenterology 1995; 108: 165-71
78. Di Martino V, Lunel F, Cadranel JF et al. Long-term effects of interferon-alpha in five HIV-positive patients with chronic hepatitis B. J Viral Hepat 1996; 3: 253-60
79. Nevens F, Main J, Honkoop P et al. Lamivudine therapy for chronic hepatitis B: A six-months randomized dose-ranging study. Gastroenterology 1997; 113: 1258-63
80. Benhamou Y, Katlama C, Lunel F et al. Effects of lamivudine on replication of hepatitis B virus in HIV-infected men. Ann Intern Med 1996; 125: 705-12
81. Batisse DP, Landau AO, Van Huen JPD et al. Natural course of hepatitis B in HIV-co-infected patients receiving highly active antiretroviral therapy including Lamivudine. Hepatology 1999: 30 (4 Pt2): 637A